Cancer Research: is basic research into cancer to identify causes and develop strategies for prevention, diagnosis, treatment, and cure. Cancer research ranges from epidemiology, molecular bioscience to the performance of clinical trials to evaluate and compare applications of the various cancer treatments. These applications include surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy. Starting in the mid-1990s, the emphasis in clinical cancer research shifted towards therapies derived from biotechnology research, such as cancer immunotherapy and gene therapy.
Applying machine learning methods to structured, expert-curated content from scientific literature is a powerful way to discover latent knowledge. Building on the QIAGEN Knowledge Base, we us...
Random drug testing is used as a preventive and detection tool for drug or alcohol use, and medication compliance in the monitoring of regulatory and treatment compliance monitoring. Urine sc...
70,237 drug overdose deaths occurred in the United States in 2017 and opioids were involved in 47,600 of those deaths (67.8%).1 Ohio had the second highest rate of opioid overdose deaths in t...
Facioscapulohumeral muscular dystrophy (FSHD), one of the most common forms of progressive muscular dystrophies and is often conventionally diagnosed by Southern blot analysis. The accurate d...
Burn patients are at risk for organ dysfunction secondary to “burn shock” and sepsis. The initial 24 hours following major burn injury presents with significant hypotension due to...
DATE: November 12, 2019TIME: 10:00am PSTDirect measurement of copy number by droplet-based shallow sequencing of genomic DNA has the potential to provide new insights into tumor heterog...
DATE: November 7, 2019TIME: 10:00am PST, 1:00pm EST Studying the pathogenesis of diabetes requires detailed analysis of the pancreatic islet microenvironment and its numerous c...
DATE: November 7, 2019 TIME: 9:00am PST, 12:00pm EST In collaboration with Hematherix and Thermo Fisher, Dr. Laurent Mosnier is investigating a new treatment for acute traumatic bl...
Since the establishment of reverse genetics techniques to manipulate the influenza virus genome, it has been possible to study viral molecular signatures responsible for virulence, and the ge...
DATE: October 31, 2019TIME: 9:00am PDT, 12:00pm EDT INTRODUCTION: A major limitation for the development of 3D engineered tissues is the absence of viable and perfusable...
DATE: October 30, 2019TIME: 7:00am PDTJoin us for a webinar to learn how to apply single cell methods to study cancer. Dr. William Greenleaf, Associate Professor from Stanford Universit...
DATE: October 29, 2019TIME: 8:00am PDTAlthough immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some pati...
The emergence of medicinal hemp represents a new frontier in medicine; one which has tremendous potential for patients struggling with a wide array of illnesses. However, in order to fully ca...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Accumulation of structural variations (SVs) across the genome is a known trigger factor for oncogenesis. Structural mutations have been clearly implicated in a number of cancers, most notably...
Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family...
Copy-number alterations and chromosomal translocations are widespread in cancer and frequently causing oncogenic mutations that drive tumorigenesis and therapy resistance. Despite their preva...
The Keynote Address will highlight eight actions that individuals can take to reduce their cancer risk. These recommendations span lifestyle modifications, cancer screening and molecular prev...
The quest to cure cancer through the manipulation the immune system has been at the forefront of science for the past half-decade. The result has been the emergence of a multitude of promisin...
The introduction of robot-assisted surgical technology into urological practice, has introduced new horizons for reducing the morbidity and enhancing the efficacy of surgery. Open radical cys...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
MIBI is a powerful platform for identifying and analyzing multiple antigens in formalin-fixed paraffin-embedded tissues. This multiplexed methodology permits the identification of 40+ protein...
Applying machine learning methods to structured, expert-curated content from scientific literature is a powerful way to discover latent knowledge. Building on the QIAGEN Knowledge Base, we us...
Random drug testing is used as a preventive and detection tool for drug or alcohol use, and medication compliance in the monitoring of regulatory and treatment compliance monitoring. Urine sc...
70,237 drug overdose deaths occurred in the United States in 2017 and opioids were involved in 47,600 of those deaths (67.8%).1 Ohio had the second highest rate of opioid overdose deaths in t...
Facioscapulohumeral muscular dystrophy (FSHD), one of the most common forms of progressive muscular dystrophies and is often conventionally diagnosed by Southern blot analysis. The accurate d...
Burn patients are at risk for organ dysfunction secondary to “burn shock” and sepsis. The initial 24 hours following major burn injury presents with significant hypotension due to...
DATE: November 12, 2019TIME: 10:00am PSTDirect measurement of copy number by droplet-based shallow sequencing of genomic DNA has the potential to provide new insights into tumor heterog...
DATE: November 7, 2019TIME: 10:00am PST, 1:00pm EST Studying the pathogenesis of diabetes requires detailed analysis of the pancreatic islet microenvironment and its numerous c...
DATE: November 7, 2019 TIME: 9:00am PST, 12:00pm EST In collaboration with Hematherix and Thermo Fisher, Dr. Laurent Mosnier is investigating a new treatment for acute traumatic bl...
Since the establishment of reverse genetics techniques to manipulate the influenza virus genome, it has been possible to study viral molecular signatures responsible for virulence, and the ge...
DATE: October 31, 2019TIME: 9:00am PDT, 12:00pm EDT INTRODUCTION: A major limitation for the development of 3D engineered tissues is the absence of viable and perfusable...
DATE: October 30, 2019TIME: 7:00am PDTJoin us for a webinar to learn how to apply single cell methods to study cancer. Dr. William Greenleaf, Associate Professor from Stanford Universit...
DATE: October 29, 2019TIME: 8:00am PDTAlthough immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some pati...
The emergence of medicinal hemp represents a new frontier in medicine; one which has tremendous potential for patients struggling with a wide array of illnesses. However, in order to fully ca...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Accumulation of structural variations (SVs) across the genome is a known trigger factor for oncogenesis. Structural mutations have been clearly implicated in a number of cancers, most notably...
Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family...
Copy-number alterations and chromosomal translocations are widespread in cancer and frequently causing oncogenic mutations that drive tumorigenesis and therapy resistance. Despite their preva...
The Keynote Address will highlight eight actions that individuals can take to reduce their cancer risk. These recommendations span lifestyle modifications, cancer screening and molecular prev...
The quest to cure cancer through the manipulation the immune system has been at the forefront of science for the past half-decade. The result has been the emergence of a multitude of promisin...
The introduction of robot-assisted surgical technology into urological practice, has introduced new horizons for reducing the morbidity and enhancing the efficacy of surgery. Open radical cys...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
MIBI is a powerful platform for identifying and analyzing multiple antigens in formalin-fixed paraffin-embedded tissues. This multiplexed methodology permits the identification of 40+ protein...